283 related articles for article (PubMed ID: 30793730)
1. The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles.
Chen D; Ganesh S; Wang W; Amiji M
Nanoscale; 2019 May; 11(18):8760-8775. PubMed ID: 30793730
[TBL] [Abstract][Full Text] [Related]
2. The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models.
Chen D; Parayath N; Ganesh S; Wang W; Amiji M
Nanoscale; 2019 Oct; 11(40):18806-18824. PubMed ID: 31595922
[TBL] [Abstract][Full Text] [Related]
3. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy.
Francia V; Schiffelers RM; Cullis PR; Witzigmann D
Bioconjug Chem; 2020 Sep; 31(9):2046-2059. PubMed ID: 32786370
[TBL] [Abstract][Full Text] [Related]
4. Role of vitronectin-rich protein corona on tumor-specific siRNA delivery and transfection with lipid nanoparticles.
Chen D; Ganesh S; Wang W; Lupieri A; Amiji M
Nanomedicine (Lond); 2021 Mar; 16(7):535-551. PubMed ID: 33683145
[No Abstract] [Full Text] [Related]
5. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
[TBL] [Abstract][Full Text] [Related]
6. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
8. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
9. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.
Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D
Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380
[TBL] [Abstract][Full Text] [Related]
10. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
11. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
12. Interaction Kinetics of Individual mRNA-Containing Lipid Nanoparticles with an Endosomal Membrane Mimic: Dependence on pH, Protein Corona Formation, and Lipoprotein Depletion.
Aliakbarinodehi N; Gallud A; Mapar M; Wesén E; Heydari S; Jing Y; Emilsson G; Liu K; Sabirsh A; Zhdanov VP; Lindfors L; Esbjörner EK; Höök F
ACS Nano; 2022 Dec; 16(12):20163-20173. PubMed ID: 36511601
[TBL] [Abstract][Full Text] [Related]
13. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles.
Dilliard SA; Sun Y; Brown MO; Sung YC; Chatterjee S; Farbiak L; Vaidya A; Lian X; Wang X; Lemoff A; Siegwart DJ
J Control Release; 2023 Sep; 361():361-372. PubMed ID: 37536547
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
16. Modulation of serum albumin protein corona for exploring cellular behaviors of fattigation-platform nanoparticles.
Nguyen VH; Meghani NM; Amin HH; Tran TTD; Tran PHL; Park C; Lee BJ
Colloids Surf B Biointerfaces; 2018 Oct; 170():179-186. PubMed ID: 29906703
[TBL] [Abstract][Full Text] [Related]
17. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
18. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
19. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
[TBL] [Abstract][Full Text] [Related]
20. Surface roughness influences the protein corona formation of glycosylated nanoparticles and alter their cellular uptake.
Piloni A; Wong CK; Chen F; Lord M; Walther A; Stenzel MH
Nanoscale; 2019 Dec; 11(48):23259-23267. PubMed ID: 31782458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
